Combination medicine for treating cancer
A cancer and drug technology, applied in the field of medicine, can solve problems such as narrow indications and easy drug resistance, and achieve strong anti-tumor effects and good synergistic effects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0046] Example 1 PARP1 inhibitors combined with FOXM1 inhibitors inhibit the growth of triple-negative breast cancer and pancreatic cancer cells in vitro:
[0047] 1. Experimental method:
[0048] (1), MTT detection of cell proliferation:
[0049] Two kinds of tumor cells were treated with DMSO (control), olaparib, FDI-6, and olaparib and FDI-6 in combination, wherein the molar ratio of olaparib and FDI-6 in the combined treatment group was 1:( 0.5~2); After 7 days, the cell proliferation was detected by MTT;
[0050] (2), colony formation assay to detect the number of cells:
[0051] The effect of combination drugs on cell proliferation was detected by clone formation assay, two kinds of tumor cells were treated with olaparib combined with FDI-6 (MDA-MB-231 olaparib 2.0μM, FDI-6 2.0μM; SW1990 olaparib 3.0 μM, FDI-6 3.0 μM); 10 days later, fix with 4% paraformaldehyde for 15 minutes, stain with crystal violet for 10 minutes, observe and take pictures with an inverted fluore...
Embodiment 2
[0062] Example 2 Olaparib combined with FDI-6 inhibits triple-negative breast cancer xenograft tumor growth in vivo
[0063] (1), the test drug:
[0064] PARP inhibitor: olaparib; FOXM1 inhibitor: FDI-6;
[0065] Preparation method: Olaparib is prepared with 10% DMSO and 10% β-cyclodextrin; FDI-6 is prepared with 10%
[0066] Prepared with DMSO, 10% Tween and 10% β-cyclodextrin;
[0067] (2), experimental animals:
[0068] BALB / cA-nude nude mice, 6-8 weeks old, female; feeding environment: SPF grade;
[0069] (3) Experimental steps:
[0070] Nude mice were subcutaneously inoculated with human triple-negative breast cancer MDA-MB-231 cells, and the tumors grew to 100-300mm 3 Afterwards, the animals were randomly divided into control group, olaparib group, FDI-6 group and combined administration group; the olaparib group was injected intraperitoneally with olaparib (60mg / kg), once a day; Group through intraperitoneal injection of FDI-6 (60mg / kg), once a day; combination gr...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com